OasisLMS

This interactive series equips clinicians with practical, evidence-based strategies for managing brain metastases in non–small cell lung cancer, covering prognosis, imaging, and multidisciplinary treatment approaches across immunotherapy, targeted therapy, surgery, and radiosurgery. Through real-world cases and guideline-informed decision points, learners apply biomarker and mutation status to personalize care for both oncogene-driven and oncogene-negative disease. We thank the Brain Metastases Subcommittee for their leadership and expertise in developing this case-based program to support confident, consistent CNS metastases management.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician associates.

Upon completion of this activity, learners should be able to:

• Discuss intracranial efficacy data of second and third-generation targeted therapies in driver mutation positive patients with brain metastases and to be able to identify sequencing with local therapy such as radiation
• Assess the adverse effects of systemic and local therapies, like radiation necrosis and the implications for patient management
• Discuss intracranial efficacy of immunotherapy alone for asymptomatic driver mutation negative brain metastases and be able to identify sequencing with local therapy such as radiation

Brain Metastasis Subcommittee

Co-Chairs

• Ullas Batra, MD, Chief Thoracic Medical Oncologist, Rajib Gandhi Cancer Institute and Research Centre | India
• Irina Veytsman, MD, Medical Oncologist, MedStar Washington Hospital Center | United States

Members

• Susan Harden, MD, Radiation Oncologist, Peter MacCallum Cancer Centre | Australia
• Jyoti Malhotra, MD, MPH, Division Chief of Thoracic Medical Oncology, City of Hope Cancer | United States
• Fabio Ynoe de Moraes, MD, PhD, Chief of Radiation Oncology, Queen's University | Canada
• Janakiraman Subramanian, MD, MPH, Director of Thoracic Oncology, Saint Luke's Hospital | United States
• Takayuki Takahama, MD, PhD, Medical Oncologist, Kindai University Hospital | Japan

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.